Cargando…
Nimotuzumab for COVID-19: case series
Background: In COVID-19, EGFR production is upregulated in the alveolar epithelial cells. EGFR overexpression further activates STAT-3 and increases lung pathology. The EGFR pathway is also one of the major nodes in pulmonary fibrosis. Methods: Nimotuzumab, a humanized anti-EGFR antibody, was used t...
Autores principales: | Abdo Cuza, Anselmo A, Ávila, Jonathan Pi, Martínez, Rafael Machado, González, José Jordán, Aspuro, Guillermo Pérez, Gutiérrez Martínez, Juan A, Suzarte, Mayra Ramos, Hernández, Danay Saavedra, Añé-Kouri, Ana L, Ramos, Tania Crombet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628863/ https://www.ncbi.nlm.nih.gov/pubmed/34806405 http://dx.doi.org/10.2217/imt-2021-0269 |
Ejemplares similares
-
Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment
por: Londres, Henrry Diaz, et al.
Publicado: (2022) -
Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience
por: Xu, Shuping, et al.
Publicado: (2016) -
An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases
por: Filgueira, Lázaro Manuel, et al.
Publicado: (2021) -
Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck
por: Crombet Ramos, Tania, et al.
Publicado: (2020) -
Nimotuzumab Increases the Recovery Rate of Severe and Critical COVID-19 Patients: Evaluation in the Real-World Scenario
por: Diaz, Henrry, et al.
Publicado: (2022)